AgomAb Therapeutics stock
AGMBNASDAQAgomAb Therapeutics N.V., HealthcareISIN US00860C1027
30Score 30 out of 100, Weak
Price and trend
54 / 100
Price history
−57% since 2026The chart shows daily closing prices since 6 Feb 2026, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Sharply down: the price has fallen very quickly lately (RSI 20).
The price is 64% below its 52-week high. Largest decline since 6 Feb 2026: 64% (June 2026 to November 2026).
Chart figures for advanced users
- SMA 50$9.74
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.36
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)20
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.36
- The lowest closing price of the last twelve months.
- Resistance$17.82
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- AgomAb Therapeutics N.V. belongs to the Biotechnology industry (Belgium) and, with a market value of $313.22M, is number 280 of 296 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- MEQIRI Score 30 out of 100 (Weak): rank 688 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $129.65M, financial debt $1.4M.Stability 54
Weaknesses
- DilutionShare count up 34% since 2022.Capital allocation 18
- Loss-makingLoss of $69.6M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 91% a year over the last 12 months.Stability 54
The score is held back by momentum and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 31 to 30.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Mar 2027in 111 days
- Last reported
- 6 Aug 2026below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −1.74+0.5%
- Revenue
- $489.9K−1.0%
- Earnings per share
- −2.04+0.5%
- Revenue
- $587.89K−1.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
3 insiders bought on the open market between 5 Oct 2026 and 21 Oct 2026, $312,970 in total.
Not counted: 2 purchases under a fixed plan (compensation, savings plan or a pre-arranged Rule 10b5-1 trading plan).
- Epstein David RPurchase
5 Nov 2026, Board
- Shares
- 15,000
- Price
- $6.90
- Value
- $103,500
- Epstein David RPurchase
21 Oct 2026, Board
- Shares
- 10,000
- Price
- $8.88
- Value
- $88,800
- Epstein David RPurchase
8 Oct 2026, Board
- Shares
- 5,000
- Price
- $8.90
- Value
- $44,500
Show 5 more
- Epstein David RPlan purchase
6 Oct 2026, Board
- Shares
- 5,000
- Price
- $8.70
- Value
- $43,500
- Kemula Pierre Thadee VictorPurchase
6 Oct 2026, Chief Financial Officer
- Shares
- 10,000
- Price
- $8.59
- Value
- $85,940
- Knotnerus Tim JasperPlan purchase
6 Oct 2026, Chief Executive Officer
- Shares
- 5,000
- Price
- $8.70
- Value
- $43,500
- Epstein David RPurchase
5 Oct 2026, Board
- Shares
- 5,000
- Price
- $8.57
- Value
- $42,850
- Knotnerus Tim JasperPurchase
5 Oct 2026, Chief Executive Officer
- Shares
- 6,000
- Price
- $8.48
- Value
- $50,880
Shares and prices per ordinary share as filed with the SEC, not per depositary receipt.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at AgomAb Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 30
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Orchestra BioMed HoldingsOBIO $361.23M49
- Eikon TherapeuticsEIKN $361.1M35
- Opus GeneticsIRD $358.57M43
- Century TherapeuticsIPSC $358.05M37
- Faeth TherapeuticsFTH $344.15M35
- Atea PharmaceuticalsAVIR $338.46M35
- Enanta PharmaceuticalsENTA $337.85M28
- Autolus TherapeuticsAUTL $330.04M31
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.